Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2007

View Archived Issues

Tego and NCI collaborate on development of fullerene formulation

Gilead reports promising phase III results for chronic hepatitis B

CytRx identifies arimoclomol dose for phase IIb trial

Positive phase I findings for topical antibiotic REP-8839

OBE-101 phase II obesity trial completes treatment

Beta-secretase inhibitor CTS-21166 begins initial phase I study

New trials commence for Heplisav

Roche completes acquisition of BioVeris

Ketasyn advances for the treatment of Alzheimer's disease

Enrollment opens for phase IIa study of KP-1461 in HIV

Intradigm selects Agilent for siRNA manufacturing

Positive results for deCODE's drug candidate DG-041 for arterial thrombosis

Molecular Insight initiates phase II pivotal registration trial for Zemiva

UCB and Biogen Idec's initiate phase II study of CDP-323 for MS

Novel SGLT inhibitors reduce postprandrial hyperglycemia in diabetic rats

DPP-IV inhibition with S-40010 enhances pancreatic beta-cell mass and reduces postprandrial glycemia

PSN-119-1: A GPR119 receptor agonist with antidiabetic and antiobesity properties

Positive results with novel selective PPARalpha agonist in diabetic monkeys

Potential targets for the treatment of sleep disorders

Amgen's new TRPV1 antagonist shows analgesic efficacy in rat pain models

Novel agents for HIV infection reported in recent Bristol-Myers Squibb patent

Novel analgesic agents imparted in recent Novartis and Novartis Pharma patents

Priority review granted for Isentress

New therapeutic agents for neurological disorders reported in recent patents

Rotarix filed for U.S. approval

Supplemental NDA filed for Nexavar in hepatocellular carcinoma

Tasigna submitted in Japan

Actos filed for use in combination with insulin in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...